Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2360Neoplasms 1709Prostatic Neoplasms 1201Lung Neoplasms 926Colorectal Neoplasms 886Carcinoma, Non-Small-Cell Lung 869Leukemia, Myeloid, Acute 593Pancreatic Neoplasms 578Multiple Myeloma 551Carcinoma, Hepatocellular 518Brain Neoplasms 516Neoplasm Metastasis 462Head and Neck Neoplasms 458Melanoma 417Ovarian Neoplasms 414Glioblastoma 403Precursor Cell Lymphoblastic Leukemia-Lymphoma 400Stomach Neoplasms 377Uterine Cervical Neoplasms 365Squamous Cell Carcinoma of Head and Neck 362Rectal Neoplasms 342Recurrence 337Sarcoma 327Hematologic Neoplasms 324Colonic Neoplasms 323Lymphoma 321Triple Negative Breast Neoplasms 291Carcinoma, Renal Cell 284Glioma 283Urinary Bladder Neoplasms 281

Interventions

Radiotherapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy × 1 year × Clear all
NCT02207465 2025-11-19

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Active not recruiting
42 enrolled
Gastrointestinal

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡